1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

 
• By Alaric DeArment

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

The Swiss dermatology company Galderma S.A. is looking to edge into a niche market for the rare disease prurigo nodularis with nemolizumab, but the company could have to face big pharma rivals in the space. Regeneron Pharmaceuticals, Inc. and Sanofi are roughly three months out from securing another potential indication for their blockbuster autoimmune disease drug Dupixent (dupilumab) for the treatment of prurigo nodularis from the US Food and Drug Administration.

Dupixent is a blockbuster drug marketed by two large pharmaceutical companies, while Galderma is an experienced dermatology player but with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.

More from R&D